[[Pluristem Therapeutics]]

CATEGORIES: Companies established in 2001, Companies listed on NASDAQ, Companies listed on TASE, Biotechnology companies of Israel, Haifa

Pluristem Therapeutics is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment.[tpl]cite web|title=Pluristem Therapeutics Inc (PSTI:NASDAQ CM)|url=http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PSTI:US|work=Bloomberg Businessweek|accessdate=22 September 2011|quote=The company engages in the development of a pipeline of products, which are derived from human placenta, a non-controversial, non-embryonic, and adult stromal cell source.[/tpl] According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.[tpl]cite web|title=Pluristem: Who we are|url=http://www.pluristem.com/index.php?option=com_content&view=article&id=6&Itemid=19|publisher=Pluristem|accessdate=22 September 2011|quote=Pluristem has made the strategic decision to work only with adult stem cells, purified from the placenta after birth and, therefore, not subject to ethical or religious controversy.[/tpl] In 2012 a procedure involving a stem cell treatment developed by Pluristem saved the life of a 7-year-old girl suffering from bone marrow aplasia.

==Corporate history==

Pluristem was founded in 2001 by Shai Meretzki of the Technion, who made use of stem cell patents he had developed with colleagues from the Weizmann Institute of Science.[tpl]cite web|title=PSTI Company Profile|url=http://www.marketwatch.com/investing/stock/psti/profile|work=MarketWatch|accessdate=22 September 2011[/tpl][tpl]cite news|last=Cohen|first=Omri|title=פלוריסטם דיווחה על הצלחת ניסוי בתרופה לטיפול בשבץ מוחי בעזרת תאי גזע - והמניה קפצה ב-150%|url=http://www.haaretz.co.il/misc/1.1317395|accessdate=22 September 2011|newspaper=Haaretz|date=9 April 2008|language=Hebrew|trans_title=Pluristem reports success in clinical trial involving drug for treating stroke using stem cells - stock soars 150%|quote=מרצקי הקים את פלוריסטם על בסיס פטנטים שפיתח עם פרופ' דב ציפורי ופרופ' אבינועם כדורי ממכון ויצמן.[/tpl] In 2003, the NASDAQ-listed shell company A1 Software acquired all shares and patents belonging to Pluristem and changed its name to Pluristem Life Systems.[tpl]cite news|last=Ovadia|first=Avishay|title=Stem cell technology co Pluristem enters Wall Street by back door|url=http://archive.globes.co.il/searchgl/Stem%20cell%20technology%20co%20Pluristem%20enters%20Wall%20Street_h_hd_0L3KsDJOtN3SmCZ8pCYveT6ri.html|accessdate=22 September 2011|newspaper=Globes|date=2 July 2003|quote=All the shares in the company have been purchased by a stock market shell by the name of A1 Software, which also recently bought all the patent and know-how rights on the technology of Dr. Shai Meretzki and others at the Technion and the Weizmann Institute relating to stem cell expansion.[/tpl][tpl]cite news|title=פלוריסיסטם הישראלית נכנסת לוול-סטריט בדלת האחורית: נרכשה על-ידי השלד הבורסאי A1 Software|url=http://www.globes.co.il/news/article.aspx?did=701943|accessdate=22 September 2011|newspaper=Globes|date=1 July 2011|language=Hebrew|trans_title=Israeli Pluristem enters Wall Street by back door: Acquired by shell company A1 Software[/tpl] In 2007 the name was changed again, this time to Pluristem Therapeutics Inc. Pluristem's shares are traded on the NASDAQ exchange and the Tel Aviv Stock Exchange, as well as on the Frankfurt Stock Exchange.
In 2007 Pluristem entered into a collaborative research agreement with the Charité medical school in Berlin for a period of five years. In 2012 Pluristem announced that the agreement had been renewed until 2017.[tpl]cite news|title=Pluristem renews German collaboration|accessdate=10 September 2012|newspaper=Globes|date=21 August 2012[/tpl] Pluristem was awarded an NIS9 million (US$2.4 million) grant from the Office of the Chief Scientist of Israel in January 2012.[tpl]cite news|title=Pluristem wins NIS 9m Chief Scientist grant|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000716827|accessdate=9 May 2012|newspaper=Globes|date=18 January 2012[/tpl] In April of the same year the company announced the receipt of an additional grant from the Chief Scientist, this time of NIS11.8 million (US$3.2 million).[tpl]cite news|last=Solomon|first=Shoshanna|title=Pluristem Heads for Two-Month High on $3.2 Million Israeli Grant|url=http://www.bloomberg.com/news/2012-04-30/pluristem-heads-for-two-month-high-on-3-2-million-israeli-grant.html|accessdate=9 May 2012|newspaper=Bloomberg|date=30 April 2012[/tpl][tpl]cite news|title=Stem cell co Pluristem awarded $3.1m chief scientist grant|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000745303|accessdate=9 May 2012|newspaper=Globes|date=1 May 2012[/tpl]

==Products==

Pluristem is in the process of clinically testing the use of its PLX (PLacental eXpanded) cells to treat peripheral arterial disease (PAD).[tpl]cite web|title=PSTI Profile|url=http://finance.yahoo.com/q/pr?s=psti|work=Yahoo! Finance|accessdate=22 September 2011|quote=The company provides PLX-PAD that has completed Phase I clinical trials for people suffering from peripheral artery disease.[/tpl] In April 2012 Pluristem announced that the U.S. Food and Drug Administration authorized Phase II clinical trials for its PLX-PAD treatment appertaining to intermittent claudication.[tpl]cite news|last=Staley|first=Eddie|title=Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial in Intermittent Claudication|url=http://www.benzinga.com/news/12/04/2502116/pluristem-receives-u-s-fda-clearance-for-phase-ii-clinical-trial-in-intermittent-|accessdate=9 May 2012|newspaper=Benzinga|date=17 April 2012[/tpl][tpl]unreliable source|date=March 2014[/tpl]
The USFDA has conferred orphan drug status on Pluristem's PLX cells for the treatment of Buerger's disease (2011) and aplastic anemia (2013).[tpl]cite news|title=Pluristem obtains orphan drug status for aplastic anemia treatment|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000824194&fid=1725|accessdate=28 February 2013|newspaper=Globes|date=21 February 2013[/tpl]

==Human applications==

In May 2012 Pluristem reported that its experimental PLacental eXpanded cells were injected into the muscles of a 7-year-old Romanian girl undergoing treatment for bone marrow aplasia disease at the Hadassah Medical Center in Jerusalem. The girl had undergone two allogenic stem cell transplants since being admitted in August 2011, both of which failed to improve her condition. Two months thereafter, with the patient's condition deteriorating rapidly, the Director of Bone Marrow Transplantation, Cell Therapy and Transplantation Research Center at Hadassah felt that all available options had been exhausted and turned to Pluristem's PLX cells. The Helsinki committee at Israel's Ministry of Health approved the procedure under compassionate use. According to Pluristem CEO Zami Aberman, it was the first time ever that stem cells were injected into the muscle rather than into the body's blood system. Pluristem announced that the treatment led to a significant increase in the girl's red cells, white cells and platelets, effecting a reverse in her condition.[tpl]cite news|last=Dey|first=Esha|title=Pluristem stem cell therapy saves a patient, shares jump|url=http://www.baltimoresun.com/health/sns-rt-us-pluristembre8480to-20120509,0,3544674.story|accessdate=9 May 2012|newspaper=The Baltimore Sun|date=9 May 2012|agency=Reuters[/tpl][tpl]cite news|title=Pluristem stem cells save girl's life|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000747466|accessdate=9 May 2012|newspaper=Globes|date=9 May 2012[/tpl][tpl]cite news|title=איך הצילו תאי הגזע של פלוריסטם את חייה של ילדה בת 7?|url=http://www.calcalist.co.il/markets/articles/0,7340,L-3570621,00.html|accessdate=9 May 2012|newspaper=Calcalist|date=9 May 2012|language=Hebrew|trans_title=How did Pluristem's stem cells save the life of a 7-year-old girl?|quote=התאים, שפיתחה חברת פלוריסטם הישראלית, הוזרקו לילדה בת 7 שהגיעה למרכז ההשתלות בבית החולים הדסה עין כרם מרומניה, כשהיא סובלת ממחלה חשוכת מרפא המונעת התחדשות של תאי מח העצם.' 'בעקבות פניית הרופא המטפל לחברת פלוריסטם ובאישור ועדת הלסינקי של משרד הבריאות, קיבלה הילדה, המאושפזת בימים אלה בבית החולים הדסה עין כרם, טיפול ניסיוני בתאי גזע מהשלייה, שפותחו בפלוריסטם.[/tpl][tpl]cite news|last=Wickman|first=Allie|title=From Earlier, Compassionate Use of Pluristem's PLX Cells Saves the Life of a Child After Bone Marrow Transplantation Failure|url=http://www.benzinga.com/news/12/05/2572600/from-earlier-compassionate-use-of-pluristems-plx-cells-saves-the-life-of-a-child-|accessdate=9 May 2012|newspaper=Benzinga|date=9 May 2012[/tpl][tpl]cite news|last=Sela|first=Rakefet|title=טיפול בתאי גזע מהשלייה של פלוריסטם הציל את חייה של ילדה|url=http://www.bizportal.co.il/shukhahon/biznews02.shtml?mid=318137&p_id=&maavar=1|accessdate=9 May 2012|newspaper=Bizportal|date=9 May 2012|language=Hebrew|trans_title=Stem cell treatment from Pluristem's placenta saved the life of a girl|quote='אנחנו הזרקנו את התאים בפעם הראשונה בעולם לתוך השריר ולא תוך מערכת הדם כמקובל בתרופות תאי גזע, זאת בחיל ורעדה לאחר שראינו תוצאות טובות בניסויים על עכברים.'[/tpl] She was released from the hospital soon after Pluristem's announcement.[tpl]cite news|last=Goldman|first=Dudi|title=Israeli innovation saves Romanian girl's life|url=http://www.ynetnews.com/articles/0,7340,L-4228036,00.html|accessdate=26 May 2012|newspaper=Ynetnews|date=12 May 2012[/tpl]
In September 2012 Pluristem reported saving the life of a third bone marrow disease patient using its PLacental eXpanded cell treatment, again at Jerusalem's Hadassah Medical Center and again under the terms of compassionate use. The 45-year-old patient suffered from acute myeloid leukemia and pancytopenia, and his condition was determined to be life-threatening. After two intramuscular injections of Pluristem's PLX cells, the patient's condition improved significantly and he was released from the hospital.[tpl]cite news|title=Pluristem stem cells save 3rd bone marrow disease patient|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000782662|accessdate=10 September 2012|newspaper=Globes|date=5 September 2012[/tpl]

==See also==

==References==

==External links==


